Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study [0.03%]
关于口服暴露前预防的指南采纳情况和使用情况的全球概要与预测研究
Robin Schaefer,Heather-Marie A Schmidt,Giovanni Ravasi et al.
Robin Schaefer et al.
Background: In 2016, the UN General Assembly set a global target of 3 million oral pre-exposure prophylaxis (PrEP) users by 2020. With this target at an end, we aimed to assess global trends in the adoption of WHO PrEP re...
Health system adaptations and considerations to facilitate optimal oral pre-exposure prophylaxis scale-up in sub-Saharan Africa [0.03%]
撒哈拉以南非洲优化口服暴露前预防规模推进的卫生系统适应性和考虑因素
Daniel K Were,Abednego Musau,Kaitlyn Atkins et al.
Daniel K Were et al.
Following WHO's 2015 recommendation, countries in sub-Saharan Africa have progressively scaled up oral pre-exposure prophylaxis (PrEP) as part of combination HIV prevention. PrEP has potential to significantly reduce new HIV infections in s...
Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study [0.03%]
新西兰EPIC-NSW扩展和延长研究：HIV暴露前预防用药在男同性恋及男男性行为者中的长期保护作用
Andrew E Grulich,Fengyi Jin,Benjamin R Bavinton et al.
Andrew E Grulich et al.
Background: Daily pre-exposure prophylaxis (PrEP) is effective in preventing HIV, but few long-term data are available on effectiveness and adherence in real-world settings. Here, we report trends in HIV incidence over 3 ...
Age patterns of HIV incidence in eastern and southern Africa: a modelling analysis of observational population-based cohort studies [0.03%]
东非和南部非洲HIV发病的年龄模式：观察性队列研究的人群为基础模型分析
Kathryn A Risher,Anne Cori,Georges Reniers et al.
Kathryn A Risher et al.
Background: As the HIV epidemic in sub-Saharan Africa matures, evidence about the age distribution of new HIV infections and how this distribution has changed over the epidemic is needed to guide HIV prevention. We aimed ...
Observational Study
The lancet. HIV. 2021 Jul;8(7):e429-e439. DOI:10.1016/S2352-3018(21)00069-2 2021
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial [0.03%]
恩曲他滨与特诺福韦艾拉酚胺和恩曲他滨与替诺福韦富马酸二酯片长期用于HIV-1预防性用药的安全性和有效性：一项随机、双盲、安慰剂对照的三期试验第96周结果
Onyema Ogbuagu,Peter J Ruane,Daniel Podzamczer et al.
Onyema Ogbuagu et al.
Background: In DISCOVER, a multinational, randomised controlled trial, emtricitabine and tenofovir alafenamide compared with emtricitabine and tenofovir disoproxil fumarate showed non-inferior efficacy for HIV prevention ...
Clinical Trial
The lancet. HIV. 2021 Jul;8(7):e397-e407. DOI:10.1016/S2352-3018(21)00071-0 2021
Salim S Abdool Karim,Cheryl Baxter
Salim S Abdool Karim
The Lancet Hiv
The Lancet Hiv